Moderna Inc (NASDAQ:MRNA, ETR:0QF) has released new modelling on the impact of its Melbourne mRNA vaccine facility, projecting billions in avoided pandemic costs and hundreds of millions in annual economic gains. The report, prepared with Oxford Economics Australia, positions the plant not only as a health safeguard but also as a long-term anchor for jobs, GDP and R&D spillovers.
The Moderna Technology Centre-Melbourne (MTC-M), opened in late 2024 at Monash University’s Clayton campus, is the first commercial-scale, end-to-end mRNA manufacturing facility in the Southern Hemisphere. At full capacity, it can produce up to 100 million vaccine doses a year across COVID-19, influenza and RSV, subject to regulatory approval.
Economic footprint
The report estimates the facility will generate around 990 direct and indirect jobs annually, alongside an annual contribution of A$220 million to GDP, plus A$124 million in flow-on benefits across the economy.
Moderna forecasts $266 million in R&D investment across Australia between 2023 and 2033, with $128 million of that in Victoria. Productivity spillovers are expected to add a further A$267 million in value nationwide, including A$117 million in Victoria, over the decade.
Pandemic preparedness dividend
The modelling suggests the facility could save $4.8 billion in economic costs over 30 years by reducing the impact of future pandemics. Roughly $3.37 billion of that is attributed to avoided health and well-being costs, such as reduced mortality, fewer lockdowns and lower mental health impacts.
These figures rest on assumptions about the frequency and severity of pandemics. While the benefits could be lower if outbreaks are less disruptive, the report argues that even under conservative scenarios, onshore mRNA capacity strengthens national resilience.
Beyond manufacturing
MTC-M’s role is framed as more than a vaccine plant. Moderna points to the facility’s potential to support clinical trials, attract global collaborations and seed an R&D ecosystem around mRNA technology. The company also highlights sovereign capability — ensuring local vaccine supply during global disruptions — as a key outcome of the investment.
About 500 jobs were created during construction, with 140 permanent roles at Moderna and up to 500 supported across supply chains, R&D and biotech partnerships.
Investor lens
For investors, the facility highlights the intersection of public health policy and biotech economics. The projections in Moderna’s report will be scrutinised against actual demand for non-COVID respiratory vaccines and the pace of regulatory approvals. Spillover benefits, too, are difficult to measure until partnerships and downstream innovations take shape.
Still, the case for sovereign mRNA capacity has resonance beyond balance sheets. Australia’s scramble for doses in 2021 underscored the costs of relying solely on imports. A domestic facility may not guarantee returns on every measure, but it does reduce exposure to global supply shocks while embedding new biotech capabilities onshore.